JOSE ANGEL
LORENTE BALANZA
PROFESOR TITULAR
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (United Kingdom) (4)
2014
2004
-
Cardiovascular effects of the nitric oxide synthase inhibitor N G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
Critical Care Medicine, Vol. 32, Núm. 1, pp. 13-20
-
Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 32, Núm. 1, pp. 21-30
1999
-
Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546c88: Effect on survival in patients with septic shock
Critical Care Medicine, Vol. 27, Núm. 1 SUPPL.